Zealand Pharma's Annual General Meeting 2021 - Seite 2

Zealand's Remuneration Report, which is subject to the regulation from the implementation of the Shareholder Rights Directive (Directive (EU) 2017/828 of 17 May 2017) in Section 139b of the Danish Companies Act, was approved by the General Meeting as proposed by the Board of Directors.

The fees for the Board of Directors for the financial year 2021 presented under agenda item 9a were approved by the General Meeting. Consequently, the proposal set forth under agenda item 9b was withdrawn accordingly by the Board of Directors as items 9a and 9b were ranked in priority (see notice published on 16 March 2021).

The Board of Directors was authorized to increase the share capital of Zealand during the period until 15 April 2026 by way of cash contribution up to nominally DKK 10,850,136 at market price and without pre-emption rights for the existing shareholders.

Zealand Pharma A/S

The Board of Directors

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.  

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
[e-mail]

Zealand Pharma Media Relations
David Rosen
Argot Partners
[e-mail]